To investigate heterogeneity in different stages of tumor progression, Losi et al. [18] analyzed KRAS, p53 mutations, and loss of heterozygosity on chromosome 5 and 18q in different areas of primary CRC lesions as well as their corresponding metastases. This evidence concerns the gene KRAS and neoplasm.